HIV Prevention and Treatment
Initiation of PrEP and PEP
- PrEP can be initiated after a negative rapid HIV antibody test, while waiting for more comprehensive laboratory test results, as recommended by the American Medical Association 1, 2
- PrEP can be started on the same day as the consultation if the rapid HIV test is negative and there are no symptoms of primary HIV infection, according to the American Medical Association 2
- A 3-medication PEP regimen is recommended for substantial HIV exposures in the last 72 hours, as per the American Medical Association guidelines 1
- PrEP can be initiated while waiting for other diagnoses and safety assessments if the HIV test results from the last 7 days are negative, as recommended by the American Medical Association 1
Transition from PEP to PrEP
- Transitioning to PrEP after completing PEP is recommended if the HIV test results are negative, to ensure continuous protection for individuals with ongoing risk of HIV exposure, as recommended by the American Medical Association 1
- Individuals with ongoing HIV exposure risk should be transitioned directly from PEP to PrEP without interruption, as recommended by the CDC and supported by the IDSA 1, 3
Monitoring during PrEP and PEP
- Quarterly HIV testing, screening for sexually transmitted infections, and renal function assessment are recommended for PrEP, as per the American Medical Association guidelines 2
- Patients with chronic hepatitis B can benefit from PrEP, as the medications used (tenofovir and emtricitabine) also have activity against the hepatitis B virus, and liver function should be monitored in these patients, as recommended by the American Medical Association 1
- A 28-day course of a three-drug antiretroviral regimen is recommended for HIV post-exposure prophylaxis, with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir plus tenofovir (alafenamide or disoproxil fumarate) plus emtricitabine (or lamivudine) as the preferred regimens, initiated as soon as possible and no later than 72 hours after exposure, as recommended by the CDC 3, 4, 5
- The complete 28-day course is essential for maximum effectiveness, with a strength of evidence based on clinical trials and observational studies 6, 4, 5
PEP Regimens and Indications
The preferred regimens for PEP are:
Regimen Components Bictegravir/emtricitabine/tenofovir alafenamide Single tablet Dolutegravir + tenofovir (alafenamide or disoproxil fumarate) + emtricitabine (or lamivudine) - Alternative regimens include TDF + 3TC (or FTC) as backbone with LPV/r or ATV/r as the third drug, with a strength of evidence based on clinical trials and observational studies 6
- PEP is indicated when exposure occurred within the past 72 hours, with a substantial risk for HIV transmission (sexual, needle-sharing, or other exposure to blood or body fluids), and the source person is known to be HIV-positive without sustained viral suppression or their viral suppression status is unknown, as recommended by the CDC 3, 4
PEP Administration and Monitoring
- Perform rapid HIV test or laboratory-based antigen/antibody combination test before PEP initiation, and do not delay the first dose while awaiting test results, as recommended by the CDC 3, 4
- Provide the full 28-day course at the initial visit, and avoid partial prescriptions ("starter packs") as evidence suggests better completion rates with full prescriptions, with a strength of evidence based on clinical trials and observational studies 6, 3
- Baseline testing for exposed individuals should include HIV antibody, hepatitis B and C serology, creatinine, and liver enzymes, as recommended by the CDC 4, 5, 3
- Schedule follow-up at 24 hours after starting PEP, and conduct laboratory testing at 4-6 weeks and 12 weeks after exposure, as recommended by the IDSA 6
- Provide enhanced adherence counseling for all individuals initiating PEP, and discuss potential side effects and management strategies, with a strength of evidence based on clinical trials and observational studies 6, 3
Special Considerations
- Avoid efavirenz (EFV) in pregnancy due to teratogenic effects, and consider the source person's history of antiretroviral medication use and viral load when selecting PEP medications to avoid potential resistance, as recommended by the CDC 7, 4
- For pregnant individuals, efavirenz (EFV) should be avoided due to teratogenic effects, and stavudine (d4T) + didanosine (ddI) combination should be avoided due to risk of fatal lactic acidosis, and indinavir (IDV) should be avoided near delivery due to risk of hyperbilirubinemia in newborns, as recommended by the CDC 4
- For children ≤10 years, the backbone regimen is Zidovudine (ZDV) + lamivudine (3TC), with lopinavir/ritonavir (LPV/r) as the preferred third drug, as recommended by the IDSA 6
- The risk/benefit of PEP should be evaluated with special consideration of drug safety in pregnancy, as recommended by the CDC and supported by the IDSA 4, 1
Effectiveness and Potential Pitfalls
- Delayed initiation of PEP beyond 72 hours significantly reduces effectiveness, and failing to complete the full 28-day regimen reduces effectiveness, as recommended by the IDSA 6, 8
- Missing follow-up appointments for monitoring and testing, and failure to consider drug resistance when selecting PEP medications, can also reduce effectiveness, with a strength of evidence based on clinical trials and observational studies 6, 3
- Overlooking transition to PrEP can lead to gaps in HIV prevention, and individuals with ongoing HIV exposure risk should be transitioned directly from PEP to PrEP without interruption, as recommended by the CDC and supported by the IDSA 1, 3
- If the source is later determined to be HIV-negative, PEP can be discontinued, as specified by the CDC and supported by the IDSA 4, 1